The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and Trulicity. This third cycle of negotiations is the first to include drugs payable under Medicare Part B, which are traditionally administered in clinical settings, in addition...
